Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

(2019) Andrzej J. Jakubowiak et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

(2019) Michael Shafique et al.   ONCOLOGIST

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

(2019) Kendra Sweet et al.   CLINICAL CANCER RESEARCH

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

(2018) Ujjawal H. Gandhi et al.   Clinical Lymphoma Myeloma & Leukemia

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

(2018) Dan T. Vogl et al.   JOURNAL OF CLINICAL ONCOLOGY

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents

(2018) Trinayan Kashyap et al.   Oncotarget

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

(2018) Nizar J. Bahlis et al.   BLOOD

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

(2016) Joel G. Turner et al.   Journal of Hematology & Oncology

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

(2016) Joel G. Turner et al.   Oncotarget

ValidNESs: a database of validated leucine-rich nuclear export signals

(2012) Szu-Chin Fu et al.   NUCLEIC ACIDS RESEARCH

Nuclear export of proteins and drug resistance in cancer

(2011) Joel G. Turner et al.   BIOCHEMICAL PHARMACOLOGY